While hereditary cancer subtypes were long considered of limited importance in the effort of defeating cancer, we now realize that they are of utmost importance in this battle. Based on recent achievements in deciphering the genetic background of breast and ovarian cancer we are facing a paradigmatic change in secondary and tertiary prevention from general screening to risk-adapted surveillance and from ‘one size fits all’ to targeted therapies. How come?
展开▼
